Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 999049 for Treatment of Men With Idiopathic Infertility
NCT05403476Phase 2Terminated
- Sponsor
- Ferring Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in idiopathic male infertility (IMI) comparing FE 999049 (Follitropin Delta) with Placebo (2 arms). Primary endpoint: Spontaneous Pregnancy Observed in Female Partner at 9 months. Started Aug 2022; status: terminated.
02
Drugs
follitropin delta
03
Conditions
idiopathic male infertility (IMI)
Beyond the preview
Go deeper on NCT05403476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403476.